Skip to main content
Grafa
Health
LTR Pharma books $19.7M cash reserves, zero debt in FY26
Image for illustrative purposes only. Not a real photo.

LTR Pharma books $19.7M cash reserves, zero debt in FY26

Share
  • LTR Pharma released its full-year financial results for FY26, reporting $19.7 million in cash reserves and zero debt as of June 30.
  • Revenue and other income fell to approximately $1.6 million from $2.1 million in FY25, while net operating cash outflows reached $10.8 million.
  • The company focuses on transitioning towards commercial launch in the US and expanding its intranasal drug delivery platform beyond erectile dysfunction into oesophageal motility disorders.

LTR Pharma (ASX:LTP) reported $19.7 million in cash with no dent for the year ended June 30, down from $31.8 million in the prior year as clinical development spending increased.

Revenue dropped from $2.1 million in FY25 to $1.6 million, which the business stated was primarily due to a lower research and development tax incentive rebate.

"We strengthened the clinical evidence supporting SPONTAN, expanded its real-world footprint in Australia and established the commercial pathway for ROXUS in the United States," stated LTR Pharma Executive Chairman Lee Rodne.

Because the release contained no executive commentary, the company detailed its progress through operational filings.

Research and development expenses increased to $6.7 million, driven by clinical trials for its SPONTAN nasal spray.

Following the announcement, the LTR Pharma share price was unchanged at $0.48.

For FY27, the company is focused on the US launch of ROXUS, clinical advancement of SPONTAN, and generating initial trial evidence for OROFLOW.

The business completed Phase II trial recruitment for SPONTAN and issued over 1,000 prescriptions in Australia via special access pathways.

LTR Pharma also signed US distribution agreements with Shed Holdings and Strive Pharmacy to establish commercial pathways for its ROXUS product.

Frequently asked questions